ONTOLOGY REPORT - ANNOTATIONS
| Term: | acrylic acid |
|
| Accession: | CHEBI:18308
|
browse the term
|
| Definition: | A monocarboxylic acid that has formula C3H4O2. |
| Synonyms: | exact_synonym: | prop-2-enoic acid |
| | related_synonym: | 2-Propenoic acid; Acrylate; C3H4O2; InChI=1S/C3H4O2/c1-2-3(4)5/h2H,1H2,(H,4,5); InChIKey=NIXOWILDQLNWCW-UHFFFAOYSA-N; OC(=O)C=C; Propenoate; Propenoic acid; Vinylformic acid; acroleic acid; ethylenecarboxylic acid |
| | alt_id: | CHEBI:19766; CHEBI:19768; CHEBI:35853; CHEBI:40714; CHEBI:8487 |
| | xref_casrn: | 79-10-7 |
| | xref: | Beilstein:635743 "Beilstein Registry Number"; ChEMBL:785373 "ChEMBL COMPOUND"; ChemIDplus:79-10-7 "CAS Registry Number"; DrugBank:DB02579 "DrugBank"; Gmelin:1817 "Gmelin Registry Number"; KEGG COMPOUND:79-10-7 "CAS Registry Number"; KEGG COMPOUND:C00511 "KEGG COMPOUND"; LIPID MAPS:LMFA01030193 "LIPID MAPS instance" |
| | xref_mesh: | MESH:C036658 |
| | xref: | NIST Chemistry WebBook:79-10-7 "CAS Registry Number"; PDBeChem:AKR "PDBeChem" |
| | cyclic_relationship: | is_conjugate_acid_of CHEBI:37080 |
|
|
acrylic acid
|
| G |
Il4 |
interleukin 4 |
|
decreases expression |
EXP |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
acrylamide
|
| G |
Abi1 |
abl-interactor 1 |
|
increases expression |
ISO |
17 |
96,576,331 |
96,648,752 |
RGD:6480464 |
CTD |
| G |
Anxa5 |
annexin A5 |
|
increases expression |
ISO |
2 |
122,949,210 |
122,979,757 |
RGD:6480464 |
CTD |
| G |
Arhgef7 |
Rho guanine nucleotide exchange factor (GEF) 7 |
|
decreases expression |
EXP |
16 |
82,521,224 |
82,603,338 |
RGD:6480464 |
CTD |
| G |
Atm |
ataxia telangiectasia mutated |
|
multiple interactions |
ISO |
8 |
56,894,746 |
56,996,565 |
RGD:6480464 |
CTD |
| G |
Atr |
ataxia telangiectasia and Rad3 related |
|
multiple interactions |
ISO |
8 |
100,936,342 |
101,014,881 |
RGD:6480464 |
CTD |
| G |
Capn2 |
calpain 2, (m/II) large subunit |
|
increases expression |
EXP |
13 |
98,473,367 |
98,524,463 |
RGD:6480464 |
CTD |
| G |
Car13 |
carbonic anhydrase 13 |
|
increases expression |
ISO |
2 |
88,271,908 |
88,309,336 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases expression |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
decreases expression |
ISO |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccl4 |
chemokine (C-C motif) ligand 4 |
|
decreases expression |
ISO |
10 |
71,759,643 |
71,761,115 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
increases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccne1 |
cyclin E1 |
|
decreases expression |
ISO |
1 |
90,568,189 |
90,577,426 |
RGD:6480464 |
CTD |
| G |
Ccnl1 |
cyclin L1 |
|
increases expression |
EXP |
2 |
155,757,335 |
155,769,633 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
affects expression |
EXP |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
decreases expression |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
increases expression |
ISO |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
decreases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
decreases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Chat |
choline O-acetyltransferase |
|
decreases activity |
EXP |
16 |
7,913,026 |
7,965,985 |
RGD:6480464 |
CTD |
| G |
Chat |
choline O-acetyltransferase |
|
multiple interactions |
EXP |
16 |
7,913,026 |
7,965,985 |
RGD:6480464 |
CTD |
| G |
Chek1 |
checkpoint kinase 1 |
|
increases expression |
ISO |
8 |
37,954,322 |
37,974,748 |
RGD:6480464 |
CTD |
| G |
Ckb |
creatine kinase, brain |
|
decreases activity |
ISO |
6 |
136,452,215 |
136,455,122 |
RGD:6480464 |
CTD |
| G |
Ckb |
creatine kinase, brain |
|
decreases activity |
EXP |
6 |
136,452,215 |
136,455,122 |
RGD:6480464 |
CTD |
| G |
Ckmt1b |
creatine kinase, mitochondrial 1B |
|
decreases activity |
ISO |
3 |
108,158,887 |
108,163,888 |
RGD:6480464 |
CTD |
| G |
Ckmt1b |
creatine kinase, mitochondrial 1B |
|
decreases activity |
EXP |
3 |
108,158,887 |
108,163,888 |
RGD:6480464 |
CTD |
| G |
Cltc |
clathrin, heavy chain (Hc) |
|
multiple interactions |
ISO |
10 |
74,976,825 |
75,032,529 |
RGD:6480464 |
CTD |
| G |
Col1a1 |
collagen, type I, alpha 1 |
|
decreases expression |
EXP |
10 |
83,622,438 |
83,639,368 |
RGD:6480464 |
CTD |
| G |
Col1a2 |
collagen, type I, alpha 2 |
|
decreases expression |
ISO |
4 |
29,393,645 |
29,428,572 |
RGD:6480464 |
CTD |
| G |
Cplx2 |
complexin 2 |
|
multiple interactions |
ISO |
17 |
16,314,592 |
16,322,938 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
increases expression |
EXP |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
decreases expression |
EXP |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects expression |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects metabolic processing |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases oxidation |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases response to substance |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases response to substance |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
increases expression |
EXP |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
5 |
19,707,159 |
19,716,856 |
RGD:6480464 |
CTD |
| G |
Ddx52 |
DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 |
|
increases expression |
EXP |
10 |
72,222,689 |
72,245,419 |
RGD:6480464 |
CTD |
| G |
Dio2 |
deiodinase, iodothyronine, type II |
|
increases expression |
EXP |
6 |
114,307,758 |
114,317,563 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
affects binding |
ISO |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Dynlrb1 |
dynein light chain roadblock-type 1 |
|
increases expression |
EXP |
3 |
145,718,890 |
145,740,187 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
affects phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases phosphorylation |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
|
increases expression |
EXP |
6 |
101,495,444 |
101,520,113 |
RGD:6480464 |
CTD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
multiple interactions |
ISO |
13 |
96,722,973 |
96,752,940 |
RGD:6480464 |
CTD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
affects metabolic processing |
ISO |
13 |
96,722,973 |
96,752,940 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
decreases phosphorylation |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
EXP |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
multiple interactions |
ISO |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fosl1 |
fos-like antigen 1 |
|
increases expression |
ISO |
1 |
208,090,612 |
208,099,118 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
decreases expression |
EXP |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Gap43 |
growth associated protein 43 |
|
decreases expression |
EXP |
11 |
59,989,085 |
60,083,971 |
RGD:6480464 |
CTD |
| G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
|
multiple interactions |
ISO |
4 |
161,282,215 |
161,286,090 |
RGD:6480464 |
CTD |
| G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
|
decreases activity |
ISO |
4 |
161,282,215 |
161,286,090 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
increases expression |
ISO |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gls |
glutaminase |
|
increases expression |
EXP |
9 |
46,380,165 |
46,452,974 |
RGD:6480464 |
CTD |
| G |
Glul |
glutamate-ammonia ligase |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
multiple interactions |
ISO |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
increases activity |
ISO |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gss |
glutathione synthetase |
|
decreases expression |
EXP |
3 |
146,057,517 |
146,087,820 |
RGD:6480464 |
CTD |
| G |
Gsta2 |
glutathione S-transferase alpha 2 |
|
increases expression |
EXP |
8 |
83,299,249 |
83,312,958 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
multiple interactions |
ISO |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
affects metabolic processing |
ISO |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
multiple interactions |
ISO |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
affects metabolic processing |
ISO |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
increases expression |
EXP |
1 |
206,627,398 |
206,629,866 |
RGD:6480464 |
CTD |
| G |
Gstt1 |
glutathione S-transferase theta 1 |
|
multiple interactions |
ISO |
20 |
13,604,355 |
13,621,456 |
RGD:6480464 |
CTD |
| G |
Gstt1 |
glutathione S-transferase theta 1 |
|
affects metabolic processing |
ISO |
20 |
13,604,355 |
13,621,456 |
RGD:6480464 |
CTD |
| G |
Gucy1a3 |
guanylate cyclase 1, soluble, alpha 3 |
|
affects expression |
EXP |
2 |
173,756,824 |
173,818,316 |
RGD:6480464 |
CTD |
| G |
Gucy1b3 |
guanylate cyclase 1, soluble, beta 3 |
|
affects expression |
EXP |
2 |
173,683,153 |
173,735,298 |
RGD:6480464 |
CTD |
| G |
Gusb |
glucuronidase, beta |
|
increases activity |
ISO |
12 |
27,744,409 |
27,757,755 |
RGD:6480464 |
CTD |
| G |
Gzmk |
granzyme K |
|
affects expression |
EXP |
2 |
44,589,295 |
44,597,386 |
RGD:6480464 |
CTD |
| G |
Hells |
helicase, lymphoid specific |
|
increases expression |
ISO |
1 |
243,246,843 |
243,262,459 |
RGD:6480464 |
CTD |
| G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
|
increases mutagenesis |
ISO |
X |
139,929,647 |
139,961,616 |
RGD:6480464 |
CTD |
| G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
|
increases mutagenesis |
ISO |
X |
139,929,647 |
139,961,616 |
RGD:6480464 |
CTD |
| G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
|
increases mutagenesis |
EXP |
X |
139,929,647 |
139,961,616 |
RGD:6480464 |
CTD |
| G |
Hsf1 |
heat shock transcription factor 1 |
|
increases phosphorylation |
ISO |
7 |
114,524,211 |
114,551,166 |
RGD:6480464 |
CTD |
| G |
Hspa8 |
heat shock 70kDa protein 8 |
|
decreases expression |
EXP |
8 |
43,784,035 |
43,787,760 |
RGD:6480464 |
CTD |
| G |
Hspa8 |
heat shock 70kDa protein 8 |
|
multiple interactions |
EXP |
8 |
43,784,035 |
43,787,760 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases expression |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Ikzf1 |
IKAROS family zinc finger 1 |
|
multiple interactions |
ISO |
14 |
92,560,200 |
92,657,336 |
RGD:6480464 |
CTD |
| G |
Ikzf1 |
IKAROS family zinc finger 1 |
|
decreases activity |
ISO |
14 |
92,560,200 |
92,657,336 |
RGD:6480464 |
CTD |
| G |
Ikzf1 |
IKAROS family zinc finger 1 |
|
decreases expression |
ISO |
14 |
92,560,200 |
92,657,336 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
decreases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1rl1 |
interleukin 1 receptor-like 1 |
|
increases expression |
ISO |
9 |
39,577,879 |
39,624,781 |
RGD:6480464 |
CTD |
| G |
Insl3 |
insulin-like 3 |
|
increases expression |
EXP |
16 |
18,890,131 |
18,891,475 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Kcne1 |
potassium voltage-gated channel, Isk-related family, member 1 |
|
multiple interactions |
ISO |
11 |
32,344,529 |
32,355,189 |
RGD:6480464 |
CTD |
| G |
Kcnq1 |
potassium voltage-gated channel, KQT-like subfamily, member 1 |
|
decreases activity |
ISO |
1 |
203,383,401 |
203,803,687 |
RGD:6480464 |
CTD |
| G |
Kcnq1 |
potassium voltage-gated channel, KQT-like subfamily, member 1 |
|
multiple interactions |
ISO |
1 |
203,383,401 |
203,803,687 |
RGD:6480464 |
CTD |
| G |
Kcnq2 |
potassium voltage-gated channel, KQT-like subfamily, member 2 |
|
increases activity |
ISO |
3 |
170,227,938 |
170,282,887 |
RGD:6480464 |
CTD |
| G |
Kcnq2 |
potassium voltage-gated channel, KQT-like subfamily, member 2 |
|
multiple interactions |
ISO |
3 |
170,227,938 |
170,282,887 |
RGD:6480464 |
CTD |
| G |
Kcnq2 |
potassium voltage-gated channel, KQT-like subfamily, member 2 |
|
affects activity |
ISO |
3 |
170,227,938 |
170,282,887 |
RGD:6480464 |
CTD |
| G |
Kcnq2 |
potassium voltage-gated channel, KQT-like subfamily, member 2 |
|
increases activity |
ISO |
3 |
170,227,938 |
170,282,887 |
RGD:6480464 |
CTD |
| G |
Kcnq2 |
potassium voltage-gated channel, KQT-like subfamily, member 2 |
|
increases activity |
ISO |
3 |
170,227,938 |
170,282,887 |
RGD:6480464 |
CTD |
| G |
Kcnq3 |
potassium voltage-gated channel, KQT-like subfamily, member 3 |
|
multiple interactions |
ISO |
7 |
103,325,185 |
103,627,045 |
RGD:6480464 |
CTD |
| G |
Kcnq4 |
potassium voltage-gated channel, KQT-like subfamily, member 4 |
|
increases activity |
ISO |
5 |
141,289,211 |
141,339,803 |
RGD:6480464 |
CTD |
| G |
Kcnq5 |
potassium voltage-gated channel, KQT-like subfamily, member 5 |
|
increases activity |
ISO |
9 |
20,181,402 |
20,767,644 |
RGD:6480464 |
CTD |
| G |
Kit |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
|
increases expression |
EXP |
14 |
34,906,043 |
34,984,819 |
RGD:6480464 |
CTD |
| G |
Lhb |
luteinizing hormone beta |
|
increases expression |
EXP |
1 |
95,892,999 |
95,893,988 |
RGD:6480464 |
CTD |
| G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
|
increases expression |
EXP |
6 |
12,613,622 |
12,651,587 |
RGD:6480464 |
CTD |
| G |
Mcm3 |
minichromosome maintenance complex component 3 |
|
increases expression |
ISO |
9 |
19,536,922 |
19,554,871 |
RGD:6480464 |
CTD |
| G |
Mki67 |
antigen identified by monoclonal antibody Ki-67 |
|
decreases expression |
ISO |
1 |
195,310,027 |
195,336,224 |
RGD:6480464 |
CTD |
| G |
Ncam1 |
neural cell adhesion molecule 1 |
|
decreases expression |
ISO |
8 |
52,822,350 |
53,120,572 |
RGD:6480464 |
CTD |
| G |
Nefl |
neurofilament, light polypeptide |
|
increases expression |
EXP |
15 |
47,636,303 |
47,640,176 |
RGD:6480464 |
CTD |
| G |
Nefl |
neurofilament, light polypeptide |
|
multiple interactions |
EXP |
15 |
47,636,303 |
47,640,176 |
RGD:6480464 |
CTD |
| G |
Nefm |
neurofilament, medium polypeptide |
|
multiple interactions |
EXP |
15 |
47,698,371 |
47,703,350 |
RGD:6480464 |
CTD |
| G |
Nefm |
neurofilament, medium polypeptide |
|
increases expression |
EXP |
15 |
47,698,371 |
47,703,350 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
EXP |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
decreases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nsf |
N-ethylmaleimide-sensitive factor |
|
multiple interactions |
ISO |
10 |
92,974,385 |
93,082,222 |
RGD:6480464 |
CTD |
| G |
Ntf3 |
neurotrophin 3 |
|
multiple interactions |
EXP |
4 |
162,435,781 |
162,506,961 |
RGD:6480464 |
CTD |
| G |
Nup54 |
nucleoporin 54 |
|
increases expression |
ISO |
14 |
17,178,761 |
17,197,062 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
increases expression |
EXP |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
decreases expression |
EXP |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pdcd2 |
programmed cell death 2 |
|
increases expression |
EXP |
1 |
54,412,081 |
54,417,571 |
RGD:6480464 |
CTD |
| G |
Phex |
phosphate regulating endopeptidase homolog, X-linked |
|
increases expression |
ISO |
X |
58,911,144 |
59,168,857 |
RGD:6480464 |
CTD |
| G |
Pik3r5 |
phosphoinositide-3-kinase, regulatory subunit 5 |
|
increases expression |
ISO |
10 |
55,227,872 |
55,248,301 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases expression |
ISO |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Ptger3 |
prostaglandin E receptor 3 (subtype EP3) |
|
multiple interactions |
ISO |
2 |
255,680,691 |
255,759,202 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
increases phosphorylation |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
multiple interactions |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
decreases phosphorylation |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Ptk2 |
protein tyrosine kinase 2 |
|
increases phosphorylation |
ISO |
7 |
110,933,298 |
111,084,554 |
RGD:6480464 |
CTD |
| G |
Ptk2b |
protein tyrosine kinase 2 beta |
|
multiple interactions |
ISO |
15 |
45,589,222 |
45,717,866 |
RGD:6480464 |
CTD |
| G |
Ptk2b |
protein tyrosine kinase 2 beta |
|
increases phosphorylation |
ISO |
15 |
45,589,222 |
45,717,866 |
RGD:6480464 |
CTD |
| G |
Rad51ap1 |
RAD51 associated protein 1 |
|
increases expression |
ISO |
4 |
163,308,788 |
163,321,854 |
RGD:6480464 |
CTD |
| G |
RGD1565421 |
similar to Sulfotransferase K2 (rSULT1C2A) |
|
increases expression |
EXP |
9 |
1,208,565 |
1,222,416 |
RGD:6480464 |
CTD |
| G |
Rif1 |
RAP1 interacting factor homolog (yeast) |
|
increases expression |
ISO |
3 |
33,574,934 |
33,624,794 |
RGD:6480464 |
CTD |
| G |
Scarb1 |
scavenger receptor class B, member 1 |
|
increases expression |
ISO |
12 |
32,390,183 |
32,457,661 |
RGD:6480464 |
CTD |
| G |
Slc14a1 |
solute carrier family 14 (urea transporter), member 1 |
|
multiple interactions |
ISO |
18 |
75,024,200 |
75,048,481 |
RGD:6480464 |
CTD |
| G |
Slc14a1 |
solute carrier family 14 (urea transporter), member 1 |
|
affects transport |
ISO |
18 |
75,024,200 |
75,048,481 |
RGD:6480464 |
CTD |
| G |
Slc1a3 |
solute carrier family 1 (glial high affinity glutamate transporter), member 3 |
|
increases expression |
EXP |
2 |
58,270,236 |
58,347,613 |
RGD:6480464 |
CTD |
| G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases expression |
ISO |
5 |
139,690,801 |
139,719,021 |
RGD:6480464 |
CTD |
| G |
Slc38a3 |
solute carrier family 38, member 3 |
|
increases expression |
EXP |
8 |
112,898,405 |
112,914,444 |
RGD:6480464 |
CTD |
| G |
Slco6b1 |
solute carrier organic anion transporter family, member 6b1 |
|
increases expression |
EXP |
9 |
96,130,052 |
96,211,483 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
decreases expression |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sra1 |
steroid receptor RNA activator 1 |
|
increases expression |
EXP |
18 |
29,306,555 |
29,309,783 |
RGD:6480464 |
CTD |
| G |
Srd5a1 |
steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) |
|
decreases expression |
EXP |
17 |
3,845,190 |
3,879,165 |
RGD:6480464 |
CTD |
| G |
Star |
steroidogenic acute regulatory protein |
|
increases expression |
EXP |
16 |
70,642,580 |
70,647,203 |
RGD:6480464 |
CTD |
| G |
Stmn1 |
stathmin 1 |
|
increases expression |
ISO |
5 |
153,226,420 |
153,232,084 |
RGD:6480464 |
CTD |
| G |
Syp |
synaptophysin |
|
increases expression |
EXP |
X |
26,890,307 |
26,905,319 |
RGD:6480464 |
CTD |
| G |
Syt1 |
synaptotagmin I |
|
multiple interactions |
ISO |
7 |
47,243,375 |
47,795,496 |
RGD:6480464 |
CTD |
| G |
Tac1 |
tachykinin, precursor 1 |
|
decreases expression |
EXP |
4 |
32,649,666 |
32,657,632 |
RGD:6480464 |
CTD |
| G |
Testin |
testin gene |
|
increases expression |
EXP |
17 |
9,532,437 |
9,544,923 |
RGD:6480464 |
CTD |
| G |
Tfrc |
transferrin receptor |
|
increases expression |
ISO |
11 |
69,976,258 |
69,998,098 |
RGD:6480464 |
CTD |
| G |
Tgm2 |
transglutaminase 2, C polypeptide |
|
decreases expression |
EXP |
3 |
148,832,866 |
148,862,385 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases mutagenesis |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
|
multiple interactions |
EXP |
10 |
60,109,656 |
60,134,939 |
RGD:6480464 |
CTD |
| G |
Tubb3 |
tubulin, beta 3 class III |
|
decreases expression |
ISO |
19 |
53,742,652 |
53,751,706 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
increases expression |
EXP |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
| G |
Tyrp1 |
tyrosinase-related protein 1 |
|
increases mutagenesis |
ISO |
5 |
99,518,306 |
99,537,289 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Zfp191 |
zinc finger protein 191 |
|
increases expression |
EXP |
18 |
15,782,909 |
15,790,125 |
RGD:6480464 |
CTD |
Term paths to the root
| Path 1 |
CHEBI ontology |
492574 |
 |
role |
482262 |
 |
chemical role |
208077 |
 |
donor |
171583 |
 |
| Bronsted acid |
148293 |
 |
oxoacid |
143579 |
 |
carbon oxoacid |
121500 |
 |
carboxylic acid |
121484 |
 |
monocarboxylic acid |
70508 |
 |
acrylic acid |
172 |
 |
| (2E)-3-[(2S,3aR,7aS)-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2,3,3a,7a-tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid |
0 |
 |
| (Z)-3-aminoacrylic acid |
0 |
 |
| (Z)-3-aminoperacrylic acid |
0 |
 |
| 2-(4-chlorophenyl)-3,3-dichloropropenoic acid |
0 |
 |
| 2-hydroxy-3-(4-hydroxyphenyl)prop-2-enoic acid |
0 |
 |
| 3-nitroacrylic acid |
0 |
 |
| acrylamide |
171 |
 |
| acryloyl group |
0 |
 |
| acryloyl-CoA |
0 |
 |
| enol-phenylpyruvic acid |
0 |
 |
| methacrylic acid + |
0 |
 |
| phosphoenolpyruvic acid |
0 |
 |
| ureidoacrylic acid |
0 |
 |
| ureidoperacrylic acid |
0 |
 |
| Path 2 |
CHEBI ontology |
492574 |
 |
subatomic particle |
491537 |
 |
composite particle |
491537 |
 |
hadron |
491537 |
 |
baryon |
491537 |
 |
nucleon |
491537 |
 |
atomic nucleus |
491537 |
 |
atom |
491537 |
 |
main group element atom |
461203 |
 |
p-block element atom |
458699 |
 |
carbon group element atom |
410677 |
 |
carbon atom |
407233 |
 |
| organic molecular entity |
407226 |
 |
organic group |
167766 |
 |
organic divalent group |
166601 |
 |
organodiyl group |
166601 |
 |
carbonyl group |
166291 |
 |
carbonyl compound |
166291 |
 |
carboxylic acid |
121484 |
 |
monocarboxylic acid |
70508 |
 |
acrylic acid |
172 |
 |
| (2E)-3-[(2S,3aR,7aS)-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2,3,3a,7a-tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid |
0 |
 |
| (Z)-3-aminoacrylic acid |
0 |
 |
| (Z)-3-aminoperacrylic acid |
0 |
 |
| 2-(4-chlorophenyl)-3,3-dichloropropenoic acid |
0 |
 |
| 2-hydroxy-3-(4-hydroxyphenyl)prop-2-enoic acid |
0 |
 |
| 3-nitroacrylic acid |
0 |
 |
| acrylamide |
171 |
 |
| acryloyl group |
0 |
 |
| acryloyl-CoA |
0 |
 |
| enol-phenylpyruvic acid |
0 |
 |
| methacrylic acid + |
0 |
 |
| phosphoenolpyruvic acid |
0 |
 |
| ureidoacrylic acid |
0 |
 |
| ureidoperacrylic acid |
0 |
 |
| |
|